Manifold MarketsGeen KYCGeverifieerde afwikkelingsgegevensRedelijk gekalibreerdHuidige gemeenschapsvoorspellingNee 68.1%
Voorspellers
6
Vraagtype
binary
Methodologie
Play-money forecasting platform
Brontype
Voorspelling
Marktdata
Bijgewerkt 3 uur geleden
Verouderd4 sep 25, 22:10 UTC31 dec 29, 23:59 UTC
Trends
Gerelateerde Markten
Gerelateerde vragen voor context, geen vergelijking van gelijkwaardige contracten.
Will MDMA-assisted therapy for PTSD be approved by the FDA before 2030?
Manifold MarketsWill a vaccine for HIV be approved by the FDA by 2030?
Manifold MarketsWill a gene therapy that edits multiple genes using CRISPR be approved by the FDA before 2030?
Manifold MarketsBefore January 1st, 2030, will any treatment for celiac disease be approved by the FDA?
Manifold MarketsHow many West Nile neuroinvasive disease cases will be reported among New York City residents in 2026?
PolymarketHantavirus pandemic in 2026?
PolymarketRegels
Resolution criteria
- Resolve YES if, by 11:59:59 pm Eastern Time on December 31, 2029, the U.S. FDA grants any marketing authorization for human use (approval, licensure, De Novo grant, or 510(k) clearance) to a product that fits this definition: a living, multicellular construct assembled ex vivo from animal or human cells, engineered to perform autonomous tasks in vivo (e.g., locomotion/drug delivery)—i.e., a “xenobot/biobot/anthrobot”-type product.
- Verification must appear in one of the FDA’s public databases: Drugs@FDA (NDAs/BLAs), Purple Book (licensed biologics), PMA, De Novo, or 510(k).
- Links: Drugs@FDA, Purple Book, PMA, De Novo, 510(k).
- (fda.gov, accessdata.fda.gov)
- EUAs, INDs/IDEs, in vitro–only/research-use-only authorizations, animal-use approvals, or products consisting solely of dissociated cells or live microbes (e.g., standard cellular therapies or live biotherapeutics) do NOT count.
